Cancer Stem Cell News Volume 10.13 | Apr 7 2021


    2021-04-07 | CSCN 10.13

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.13 – 07 April, 2021

    BCL3 Couples Cancer Stem Cell Enrichment with Pancreatic Cancer Molecular Subtypes

    Scientists demonstrated that Bcl3 impacted pancreatic carcinogenesis by restraining CSC expansion and by curtailing an aggressive and metastatic tumor burden in pancreatic ductal adenocarcinoma across species.

    AbstractGraphical Abstract

    Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
    PUBLICATIONSRanked by the impact factor of the journal

    miR-146 Connects Stem Cell Identity with Metabolism and Pharmacological Resistance in Breast Cancer

    Researchers showed that miR-146 was relevant for normal mammary stem cell and mammary cancer stem cell activity.
    [Journal of Cell Biology]

    Full Article

    Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia

    Scientists found that leukemic stem cells in chronic myelomonocytic leukemia resided in a CD34+/CD38 fraction of the malignant clone.


    C3G Downregulation Induces the Acquisition of a Mesenchymal Phenotype That Enhances Aggressiveness of Glioblastoma Cells

    The authors report that C3G downregulation promoted the acquisition of a more mesenchymal phenotype that enhanced the migratory and invasive capacity of glioblastoma cells.
    [Cell Death & Disease]

    Full Article

    Silencing PTEN in the Fallopian Tube Promotes Enrichment of Cancer Stem Cell-Like Function through Loss of PAX2

    Loss of PTEN in fallopian tube epithelium led to the enrichment of CSC markers such as LGR5, WNT4, ALDH1, CD44.
    [Cell Death & Disease]

    Full Article

    ISG15 Is Downregulated by KLF12 and Implicated in Maintenance of Cancer Stem Cell-Like Features in Cisplatin-Resistant Ovarian Cancer

    Investigators identified that both ectopic wild type and nonISGylatable mutant interferon‐stimulated gene 15 (ISG15) expression inhibited CSC‐like phenotypes of cisplatin‐resistant ovarian cancer cells.
    [Journal of Cellular and Molecular Medicine]

    Full Article

    Nitidine Chloride Suppresses Epithelial-Mesenchymal Transition and Stem Cell-Like Properties in Glioblastoma by Regulating JAK2/STAT3 Signaling

    Researchers investigated the inhibitory effect of nitidine chloride on the epithelial‐mesenchymal transition process and stem cell‐like properties in glioma cells.
    [Cancer Medicine]

    Full Article

    Tideglusib Suppresses Stem-Cell-Like Features and Progression of Osteosarcoma by Inhibiting GSK-3β/NOTCH1 Signaling

    The authors found that tideglusib (TID) markedly reduced the cell viability of different osteosarcoma cell lines. Cell cycle arrest distributed in G2/M was markedly up-regulated in TID-incubated osteosarcoma cells through enhancing p21 expression levels.
    [Biochemical and Biophysical Research Communications]


    The AXL-PYK2-PKCα Axis as a Nexus of Stemness Circuits in TNBC

    Scientists identified a clinically relevant signaling nexus mediated by AXL receptor, PYK2 and PKCα and show its impact on stemness in triple-negative breast cancer.
    [Life Science Alliance]

    Full Article
    Explore scientific events this April with the Science Events Calendar.

    Breast Cancer as an Example of Tumor Heterogeneity and Tumor Cell Plasticity during Malignant Progression

    Investigators used breast cancer as an example of the origins of tumor heterogeneity and of tumor cell plasticity, as well as considering interclonal cooperativity and cell plasticity as sources of cancer cell heterogeneity.
    [British Journal of Cancer]

    Full Article

    Cancer and Stem Cells

    The authors made an attempt to scrutinize evidence that indicates the role of stem cells in tumorigenesis and metastasis, and cancer relapse.
    [Experimental Biology and Medicine]


    Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

    Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
    [Bio-Path Holdings, Inc.]

    Press Release

    Turning Point Therapeutics Announces Initial Clinical Data from Phase I/II SWORD-1 Study of RET Inhibitor TPX-0046

    Turning Point Therapeutics, Inc. a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase I/II SWORD-1 study of its RET inhibitor drug candidate, TPX-0046.
    [Turning Point Therapeutics, Inc. (Globe Newswire, Inc.)]

    Press Release

    Kite Submits Supplemental Biologics License Application to US Food and Drug Administration for Tecartus® in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

    Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
    [Kite (BusinessWire, Inc.)]

    Press Release


    Cancer Stem Cells: Advances in Biology and Clinical Translation

    May 19 – 21, 2021

    > See All Events


    Postdoctoral Fellow or Research Scientist – Cell and Gene Therapy of Cancer

    Rutgers University – New Brunswick, New Jersey, United States

    Postdoctoral Fellowship – Breast Cancer Immunology and Immunotherapy

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Journal Editor – Blood Cancer Discovery and Cancer Immunology

    American Association for Cancer Research – Boston, Massachusetts, United States

    Postdoctoral Fellow – Myeloma Tumor Microenvironment

    Moores Cancer Center – La Jolla, California, United States

    Medicinal Chemist – Muscle-Wasting, Neurodegeneration, and Oncology

    Almac – Belfast, Ireland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter